|Bid||5.17 x 2900|
|Ask||5.52 x 2900|
|Day's Range||5.20 - 5.57|
|52 Week Range||4.70 - 32.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.33|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
Evanston, IL-based biopharma company Aptinyx Inc. is tanking Wednesday after the phase 2 trial for the company's diabetic peripheral neuropathy treatment did not meet its primary endpoint. The company said that the trial did not demonstrate statistically significant separation in outcomes when compared to a placebo in the double-blind controlled study of 300 patients suffering from the disease.
Shares of Aptinyx Inc. fell 67% in premarket trade Wednesday after the biotech company announced that the phase 2 study of its treatment for painful diabetic peripheral neuropathy did not meet its primary endpoint. The therapy, NYX-2925, did not show a significant difference in patients' daily pain scores compared to placebo, Aptinyx said. The company said it is also conducting an exploratory phase 2 study of NYX-2925 in patients with fibromyalgia, and said a full analysis of the data should be available in the first half of 2019. Shares of Aptinyx have gained 7.8% in the year through Tuesday, while the S&P 500 has gained 4.1%. The iShares Nasdaq Biotechnology ETF has gained 13.3%.
NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects.
EVANSTON, Ill., Jan. 02, 2019 -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference. The fireside chat will take place at 10:00 a.m. ET on December 12, 2018 at the Mandarin Oriental New York Hotel in New York City. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com.
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study receive daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in.
NYX-2925 is a novel modulator of NMDA receptors and its development for painful DPN has been granted Fast Track designation by the U.S. Food and Drug Administration. The company expects to announce top-line data from the study early in the first quarter of 2019.
EVANSTON, Ill., Oct. 29, 2018 -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and.
EVANSTON, Ill. , June 25, 2018 /PRNewswire/ -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel, proprietary, synthetic small ...